In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment

Digestive Diseases and Sciences

Volumn 56, Issue 12, 2011, Pages 3624-3630

  Rudolph, G ^a   Gotthardt, D N ^a   Kloeters Plachky, P ^a   Kulaksiz, H ^b   Schirmacher, P ^c   Stiehl, A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Colonic carcinomas; Inflammatory bowel disease; Sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COLITIS; COLON CARCINOMA; DISEASE ASSOCIATION; DRUG DOSE INCREASE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SCHOOL CHILD; TREATMENT DURATION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COLONOSCOPY; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; GERMANY; MIDDLE AGED; RISK FACTOR; SCLEROSING CHOLANGITIS; TIME;

ADOLESCENT; ADULT; AGED; CHILD; CHOLAGOGUES AND CHOLERETICS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; COLONOSCOPY; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 84856174030     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1763-2     Document Type: Article

References (46)

1. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis-a review of its clinical features, cholangiography and hepatic histology. Gut. 1980;21:870-877. (Pubitemid 11198911)
2. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79:200-206. (Pubitemid 10046359)
3. Farrant MJ, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710-1717.
4. Lee Y-M, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924-933.
5. Broome U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610-615. (Pubitemid 26111384)
6. Brenntnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1996;110:331-338. (Pubitemid 26043863)
7. Shetti K, Rybicki L, Brezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis in patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94:1643-1649. (Pubitemid 29260459)
8. Broome U, Löfberg R, Veress B, Erikson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404-1408.
9. Gurbuz AK, Giardello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum. 1995;89:37-41.
10. Loftus EV, Sandborn WJ, Tremaine WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996;110:432-440. (Pubitemid 26043876)
11. Kornfeld D, Ekbom A, Ihre T. Is there an excess of colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41: 522-525.
12. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Sem Liv Dis. 2006;26:31-41. (Pubitemid 43320725)
13. Claessen MMH, Vleggaar FP, Tytgat MAJ, Siersema PD, Van Buuren HR. High life-time risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158-164.
14. Tung BY, Edmond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in cholangitis. Ann Intern Med. 2001;134:89-95.
15. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-893. (Pubitemid 36389790)
16. Thakeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2010;9:52-56.
17. Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149-155.
18. Ghazale A, Chari St, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706-715. (Pubitemid 351312724)
19. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebocontrolled study period. J Hepatol. 1994;20:57-64. (Pubitemid 24043086)
20. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology. 1992;16:707-714.
21. Lindor KD, the Mayo PSC/UDCA study group. Ursodiol for the treatment of primary sclerosing cholangitis. N Engl J Med. 1997;336:691-695.
22. Mitchell SA, Bansi DS, Hunt N, von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled study. Gastroenterology. 2001; 121:900-907. (Pubitemid 32959399)
23. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96: 1558-1562. (Pubitemid 32455090)
24. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis. A five year multicenter randomized controlled study. Gastroenterology. 2005;129:1464-1472. (Pubitemid 41597389)
25. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman W. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008;48: 792-800.
26. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of highdose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology. 2004;40:693-698. (Pubitemid 39265592)
27. Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8 years prospective study. J Hepatol. 1997;26:560-566. (Pubitemid 27112721)
28. Stiehl A, Rudolph G, Klöters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36: 151-156. (Pubitemid 34146420)
29. Stiehl A. Primary sclerosing cholangitis: the role of endoscopic therapy. Sem Liv Dis. 2006;26:62-68. (Pubitemid 43320728)
30. Gotthardt D, Rudolph G, Klöters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic dilatation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc. 2010;71:527-534.
31. Gotthardt D, Stiehl A. Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis. Clin Liver Dis. 2010;14:349-358.
32. Kulaksiz H, Rudolph G, Kloeters-Plachky P, Sauer P, Geiss H, Stiehl A. Biliary Candida infections in primary sclerosing cholangitis. J Hepatol. 2006;45:711-716. (Pubitemid 44479874)
33. Woolson RF. Rank tests and a one-sample log rank test for comparing observed survival data to a standard population. Biometrics. 1981;37:687-696.
34. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982;69:553-566.
35. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2007;19:487-491. (Pubitemid 46725755)
36. Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A. In PSC with dominant stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol. 2010;53:313-317.
37. Earnest D, Holubec H, Wali RK, et al. Chemoprevention of azomethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994;54:5071-5074.
38. Khare S, Cerda S, Wali RK, et al. Ursodeoxycholic acid inhibits RAS mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res. 2003;63:3517-3523. (Pubitemid 36793030)
39. Garioud A, Seksik P, Chretien Y, et al. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22: 842-847.
40. Lindor KD, Knowdley KV, Luketic VAC, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:671-673.
41. Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic acid and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology. 1990;98:424-428. (Pubitemid 20037926)
42. Batta AK, Salen G, Arora R, et al. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology. 1989;10:414-419. (Pubitemid 19256549)
43. Fedorowski T, Salen G, Tint GS, Mosbach E. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology. 1979;77:1068-1073.
44. Fromm H, Carlson GL, Hofmann AF, Farivar S. Amin P: Metabolism in man of 7-ketolithocholic acid, precursor of chenoand ursodeoxycholic acid. Am J Phsiol. 1980;239:G161-G166. (Pubitemid 10002612)
45. Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol. 1995;23:283-289.
46. Eaton J, Silveira MG, Lindor K. High dose ursodeoxycholic acid is associated with the development of colorectal neopolasia in patients with ulcerative colitis and primary sclerosing cholangitis. Hepatology. 2010;52:356A.